Sector News

Biogen announces billion-franc drugs plant

July 1, 2015
Life sciences
Biogen, an international biotechnology company, announced on Tuesday plans to invest one billion francs ($1.06 billion) for a new drug manufacturing plant in Luterbach in the canton of Solothurn.
 
The company told a press conference with officials from the canton that work would begin on the plant at the end of this year with completion set for the end of 2018.
 
By 2019 the plant should be operational, creating 400 jobs and producing biopharmaceutical medicine, Biogen said.
 
The plant would be the fifth for the company in the world.
 
Founded in 1978 by a group of biologists in Geneva, the company has grown to employ 7,500 people with operations in 30 countries and annual revenues of $5 billion.
 
With corporate headquarters in Massachusetts and international headquarters in the canton of Zug, the company says it is committed to discovering, developing and delivering therapies to patients with neurodegenerative diseases, autoimmune disorders and hemophilia, according to its website.
 
Biogen said it has several new drugs in the pipeline that have created the need for additional production capacity.
 
“Thanks to excellent support from the canton of Solothurn, the municipality of Luterbach and the federal government, we have the opportunity to build the most advanced production facilities in the world,” Natascha Schill, CEO of Biogen Switzerland, said in a statement.
 
She said Solothurn “offers a business-friendly environment, reliable infrastructure, and access to well-trained labour.”
 
As well, Schill noted that Biogen already had its international headquarters in Switzerland.
 
“All these factors contribute to the fact that we want to expand our global production network in Luterbach.” 
 
The canton of Solothurn said a preliminary agreement had been signed with Biogen.
 
But it said a period of public consultation was needed, with a municipal meeting planned later this week to gather feedback.
 
Interpharma, the association of research-based pharmaceutical companies in Switzerland, welcomed Biogen’s announcement.
 
It is a clear sign of the “attractiveness of Switzerland” as a location for the pharmaceutical industry, Interpharma spokesman Thomas Cueni is quoted as saying by the Tages Anzeiger newspaper.
 

comments closed

Related News

September 25, 2022

Rise of the machines: Novo Nordisk pledges $200M to create first quantum computer for life sciences

Life sciences

Big Pharma has long seen the potential for AI and machine learning to accelerate drug development. But Novo Nordisk is going a step further by channeling $200 million toward the creation of a computer that will outrun anything in existence.

September 25, 2022

Mount Sinai AI uncovers new brain analysis method to predict dementia, Alzheimer’s disease

Life sciences

Current methods for diagnosing Alzheimer’s disease rely on a complex combination of self- and caregiver-reported symptoms, a physical examination and either a PET scan or a spinal tap to look for evidence of amyloid plaque build-ups in the brain. But a new artificial intelligence-based method may make the diagnostic process a much more objective one.

September 25, 2022

New AstraZeneca-backed report finds big money behind diverse owners and entrepreneurs in Europe

Life sciences

There is lots of talk about diversity and inclusion in business, including in pharma and medtech. A new report by the Open Political Economy Network (OPEN), a think tank focusing on migration and diversity, released its “Minority Businesses Matter: Europe” report highlighting the successes and challenges of ethnic minority-owned businesses in Europe.